June 18, 2008--Amgen announced that the supplemental Biologics License Application (sBLA) for ENBREL for the treatment of pediatric patients with chronic moderate to severe plaque psoriasis who have tried another therapy will be discussed today at a meeting of the DODAC. Moderate to severe plaque psoriasis is a serious, chronic inflammatory disease that can have both physical and psychosocial impact. According to a study published in the British Journal of Dermatology, chronic psoriasis can have as much of an impact on a child's physical, psychological and social functioning as other serious childhood diseases such as asthma, epilepsy and diabetes.
The whole story can be read here.
No comments:
Post a Comment